anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: To compare the effectiveness and feasibility of the measurement-based care (MBC) in the treatment of depression with clinician's treatment decisions, standardizing treatment (ST, clinicians' choice decisions) to two commonly prescribed antidepressants.

Methods: Selecting the patients in psychiatric hospitals and general hospitals with depression, with multi-center randomized controlled study design. Refer to STAR-D "measurement-based care" mode, to establish the whole measurement-based evaluation system. Eligible patients will be randomly assigned to 24 weeks of MBC or ST, restricting treatment to paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) in both groups. the ST group will maximize simulate of the actual clinical situation, and the patients of the MBC group are required to complete the prospective Life-chart Methodology (LCM-p), 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16) and other related symptoms and side effects of self-assessment, the doctor will make a comprehensive assessment according to the results of self-assessment, adjust treatment according to research programs. This is 1-year follow-up study; the independent members will have a blinded assessment in the baseline visit and each point of view. Depressive symptoms are measured using the Hamilton Rating Scale for Depression (HAMD) and QIDS-SR.
A composition comprising a carbonaceous material and an active particle positioned on the carbonaceous material and comprising silver, gold, zinc, copper, magnesium, selenium, platinum, arsenic, cobalt, calcium, silicon, or any combination thereof is provided. The carbonaceous material is preferably an activated carbon fibre, an activated carbon powder, a charcoal material, a bamboo charcoal granule, a carbon black, a graphite powder, an expanded graphite powder, a graphene, a nano carbon powder, or a carbon powder made from phenol formaldehyde resins or artificial resins. The carbonaceous material may contain a pore and may have an acidic or a basic group. The compositions may further comprise an additive. A composition, comprising the said carbonaceous material and active particle, for use in the treatment of intestinal cancer is provided. The intestinal cancer is preferably colon cancer, rectal cancer or colorectal cancer.
PROBLEM TO BE SOLVED: To provide a new compound consisting of a separated polypeptide containing an amino acid sequence having high identity to a specific amino acid sequence and useful e.g. for the treatment and diagnosis of hypercardia, cardiac failure, ischemia, arrhythmia, hypertension, atherosclerosis, cancer, etc. SOLUTION: This new polypeptide is a separated polypeptide containing an amino acid sequence having identity of >=70% to the amino acid sequence of the formula I and a separated polypeptide containing an amino acid sequence having identity of >=70% to the amino acid sequence of the formula II. It is useful e.g. for the treatment and diagnostic assay of hypercardia, cardiac failure, ischemia, arrhythmia, hypertension, atherosclerosis, restenosis, chronic and acute inflammation, cerebral attack, rheumatoid arthritis, disseminated sclerosis, intestinal disease, diabetes, cancer, etc. The polypeptide can be produced from a cDNA library originated from mRNA in a cell such as human brain, heart or fetus dura cell by preparing a gene from the library by standard cloning and screening technique and expressing the gene in a host cell by recombination technique.
Infertility is a disease of impaired fertility. With socioeconomic development, changes in human lifestyles, and increased environmental pollution, the problem of low human fertility has become increasingly prominent. The incidence of global infertility is increasing every year. Many factors lead to infertility, and common female factors include tubal factors, ovulation disorders, endometriosis, and immune factors. The gut microbiota is involved in many physiological processes, such as nutrient absorption, intestinal mucosal growth, glycolipid metabolism, and immune system regulation. An altered gut flora is associated with female infertility disorders such as polycystic ovary syndrome (PCOS), endometriosis (EMs), and premature ovarian failure (POF). Dysbiosis of the gut microbiota directly or indirectly contributes to the development of female infertility disorders, which also affect the homeostasis of the gut microbiota. Identifying the etiology and pathogenesis of infertility in patients is the focus of reproductive medicine physicians. We studied the developmental mechanism between the gut microbiota and PCOS, EMs, and POF from a new perspective, providing new ideas for diagnosing and treating female infertility diseases and specific reference values for eugenics.
FIELD: pharmaceutical chemistry and biotechnology. ^ SUBSTANCE: invention relates to highly purified lipopeptide antibiotic and pharmaceutical compositions comprising this compound. Invention also discloses daptomycin purification method including a series of consecutive stages of anion-exchange chromatography, hydrophobic chromatography, and anion-exchange chromatography as well as a method for purification of daptomycin using anion-exchange chromatography enhanced by modified buffer. Invention discloses improved method for production of daptomycin via fermentation of Streptomyces roseosporus followed by purification stage. Invention further discloses using high-efficiency liquid chromatography methods for checking purity of daptomycin. Disclosed are likewise lipopeptide micelles and methods for making these micelles as well as use of lipopeptide micelles in purification of lipopeptide antibiotics, such as daptomycin, and therapeutical application thereof. Invention allows preparation of lipopeptide antibiotics with 95 to 98% purity. ^ EFFECT: increased antibacterial activity of lipopeptide antibiotics against gram-positive microflora. ^ 68 cl, 19 dwg, 3 tbl, 18 ex
BACKGROUND: Emerging data suggested a favorable outcome in advanced non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD) patients treated by immunotherapy. The objective of this study was to investigate the effectiveness of neoadjuvant immunotherapy among NSCLC with COPD versus NSCLC without COPD and explore the potential mechanistic links.
PATIENTS AND METHODS: Patients with NSCLC receiving neoadjuvant immunotherapy and surgery at Shanghai Pulmonary Hospital between November 2020 and January 2023 were reviewed. The assessment of neoadjuvant immunotherapy's effectiveness was conducted based on the major pathologic response (MPR). The gene expression profile was investigated by RNA sequencing data. Immune cell proportions were examined using flow cytometry. The association between gene expression, immune cells, and pathologic response was validated by immunohistochemistry and single-cell data.
RESULTS: A total of 230 NSCLC patients who received neoadjuvant immunotherapy were analyzed, including 60 (26.1%) with COPD. Multivariate logistic regression demonstrated that COPD was a predictor for MPR after neoadjuvant immunotherapy [odds ratio (OR), 2.490; 95% confidence interval (CI), 1.295-4.912; P = 0.007]. NSCLC with COPD showed a down-regulation of HERV-H LTR-associating protein 2 (HHLA2), which was an immune checkpoint molecule, and the HHLA2low group demonstrated the enrichment of CD8+CD103+ tissue-resident memory T cells (TRM) compared to the HHLA2high group (11.9% vs. 4.2%, P = 0.013). Single-cell analysis revealed TRM enrichment in the MPR group. Similarly, NSCLC with COPD exhibited a higher proportion of CD8+CD103+TRM compared to NSCLC without COPD (11.9% vs. 4.6%, P = 0.040).
CONCLUSIONS: The study identified NSCLC with COPD as a favorable lung cancer type for neoadjuvant immunotherapy, offering a new perspective on the multimodality treatment of this patient population. Down-regulated HHLA2 in NSCLC with COPD might improve the MPR rate to neoadjuvant immunotherapy owing to the enrichment of CD8+CD103+TRM.
TRIAL REGISTRATION: Approval for the collection and utilization of clinical samples was granted by the Ethics Committee of Shanghai Pulmonary Hospital (Approval number: K23-228).
GWP42003-P oral solution (100 mg/milliliter \[mL\] cannabidiol in sesame oil with anhydrous ethanol with added sweetener \[sucralose\] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
Use of Depo-Provera CI reduces serum estrogen levels and is associated with significant loss of bone mineral density (BMD). This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if use of Depo-Provera CI by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.

A study to assess the reversibility of loss of BMD in adolescents was conducted with Depo-Provera CI. After discontinuing Depo-Provera CI in these adolescents, mean BMD loss at the total hip and femoral neck did not fully recover by 5 years (60 months) post-treatment in the sub-group of adolescents who were treated for more than 2 years [see Clinical Studies (14.3)]. Similarly, in adults, there was only partial recovery of mean BMD at the total hip, femoral neck, and lumbar spine towards baseline by 2 years post-treatment [see Clinical Studies (14.2)].

The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. BMD should be evaluated when a woman needs to continue to use Depo-Provera CI long-term. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity.

Other birth control methods should be considered in the risk/benefit analysis for the use of Depo-Provera CI in women with osteoporosis risk factors. Depo-Provera CI can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids).
It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.
Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10\^7 cells/10 mL (range: 4.5 x 10\^7 to 5.5 x 10\^7 cells/10 mL) via the hepatic artery.
The emergence of Dimethyl Fumarate (DMF) as an oral agent for the treatment of relapsing multiple sclerosis (MS) has the potential to reduce the burden of neurologic disability while minimizing side effects and risks associated with more established therapies. However, at present there is a need for further understanding of the mechanisms of action for DMF. That is, it is not yet known whether the benefits observed in MS patients treated with DMF are due primarily to immunologic and anti-inflammatory effects or neuroprotective effects, or both. The main site(s) of DMF actions, whether in the CNS and/or the periphery, is also not known.

Dimethyl fumarate is believed to act centrally by enhancing the nuclear factor erythroid 2 related factor 2 (Nrf2) transcriptional pathway, which regulates enzymes to counter act oxidative stress . DMF may enhance the Nrf2 transcriptional pathway within the CNS, but this is unproven. DMF is also anti-inflammatory, and is known to inhibit NFB translocation to the nucleus \[and chemokine-induced monocyte chemotaxis. Inhibition of NFB could occur systemically, or within the CNS, or both. Therefore, investigators intend to investigate antioxidant and immunologic changes within the central nervous system (CNS) and blood in relation to DMF therapy.
BACKGROUND: Recent trials suggest that more conservative resections such as segmentectomy are non-inferior to more radical approaches. Most segmentectomy can be safely performed using video-assisted thoracoscopic surgery (VATS). The clinical benefits of robotic-assisted thoracoscopic surgery (RATS) remain unclear. We aimed to perform a systematic review evaluating the outcome of open thoracotomy, VATS, and RATS for segmentectomy.
METHODS: A systematic database search was conducted of original articles exploring the outcome of open versus VATS versus RATS segmentectomy in PubMed, EMBASE and SCOPUS. The primary outcome was 30-day mortality. Secondary outcomes were hospital readmission, air leak, and post-operative pneumonia respectively.
RESULTS: 11 studies were included with a total patient sample size of 7280. There were no differences between the three approaches in terms of 30-day mortality, hospital readmission, air leak, and post-operative pneumonia.
CONCLUSION: There are no significant differences between the three approaches in the clinical outcomes measured. While our analysis demonstrates the potential benefits of RATS, it is important to note that the steep learning curve associated with this technique may impact its wider adoption and efficacy in the community. Further randomised control studies are required to compare the short and long terms results of VATS and RATS approaches.
The invention discloses a traditional Chinese medicine preparation used for treating varicocele, belonging to the field of traditional Chinese medicine. The traditional Chinese medicine preparation used for treating varicocele is prepared by the following materials according to a certain weight account: 10g honeysuckle flower, Chinese dodder seed, achyranthes root, coptis root, red peony root, cape jasmine fruit and forsythia fruit each, 15g beautiful sweetgum fruit, 10g amur corktree bark, and 10g baikal skullcap root. The preparation process of the Chinese medicine comprises that: first, removing the impurity in each raw medicine, then putting the medicine into a marmite with water of 500 ml for boiling for half an hour. One dose is divided into two shares served separately per day. The invention has the function of warming yang, replenishing vital essence, tonifying the kidney and arresting discharge. The invention is characterized by rich material source, low price, easy acquisition and no toxic and side effects.
Cpds. of gen. formula (I): (where R is Cl or Br) are prepd. by reacting a cpd. (II): with elemental bromine in a ratio of 1:1 to 1:2.3 in inert organic solvent, opt. using catalysing initiating agents such as light or dibenzylperoxide at room temp. to max. 100 degrees C to form a cpd. (III): (where R1 is H or Br) and heating (III) opt. in the presence of organic solvent at 100-200 degrees C. Prefd. solvents for the bromination reaction are halogenated hydrocarbons. Solvents for reaction of (III) are halogenated hydrocarbons, or solvents which react with Br themselves such as paraffin oil, tetrahydronaphthaline, xylene, carboxylic acids or -anhydrides, used in equal quantities as (III). (I) are inters. for medicaments, esp. for psychopharmaca and anticonvulsives. The process is simpler than known processes, giving a high yield and purity. Isolation and purification of (III) which has skin-toxicity, is not necessary.
Patients undergoing cardiac surgery (CVS) have various indications for anticoagulation, with the most common being pre-existing atrial fibrillation (AF) or post-operative atrial fibrillation (POAF). The incidence of POAF is up to 42% and both pre-existing AF and POAF have been associated with 62% higher odds of stroke and 44% higher odds of mortality. Even though non-vitamin K oral anticoagulants (NOACs) have superseded warfarin as the choice anticoagulant for non-valvular AF based on the results of landmark trials, these trials generally excluded patients with recent CVS. Although recommendations on anticoagulation for POAF are extrapolated from general AF guidelines, there is hesitancy to use NOACs early after cardiac surgery due to concerns regarding hemorrhagic cardiac tamponade and the fast anticoagulant onset of these agents with limited access to reversal agents. The investigators recently conducted a systematic review of 7 studies evaluating NOACs in the post-CVS setting, which identified insufficient evidence regarding the safety and efficacy of NOACs versus warfarin. Despite there being 3 planned randomized controlled trials (RCT) comparing NOACs to warfarin early following cardiac surgery, none indicated a standardized bridging protocol, which is a significant limitation, as anticoagulation trials lacking in standardized bridging may significantly influence incidences of bleeding and embolic events. The investigators propose a multi-centered pilot RCT of 100 patients comparing NOACs to warfarin initiated early after cardiac surgery (ie. within the index hospitalization) to determine the feasibility of conducting a large, definitive RCT. Patients with an indication for anticoagulation (most common being pre-existing AF or POAF), will be randomized to receive a NOAC (starting on post-operative day \[POD\] 5 or later) or warfarin (starting on POD 1 or at time of diagnosis of indication for anticoagulation) and supported by a standardized bridging protocol with unfractionated heparin infusion or low molecular weight heparin as early as POD 3 in patients with high-risk of thrombosis and low risk of bleeding. The co-primary feasibility outcomes are (1) \>70% of eligible patients recruited into the study, and (2) \>80% adherence to the anticoagulation protocol (defined as adherence to the bridging protocol and the initiation of the study drug on the right POD). The primary scientific outcome is a composite of death, stroke or systemic embolism, major bleeding, or pericardial effusion requiring intervention. Follow up will be conducted at 1 and 3 months and corroborated by re-admission data. The results of this pilot RCT will inform the design and feasibility of a large definitive RCT.
BACKGROUND AND AIMS: Recently, the location-based resect-and-discard (LBRD) strategy, which does not depend on optical diagnosis, was developed and demonstrated different surveillance interval agreement with the pathology-based reference in several researches. We aimed to evaluate the performance of LBRD in our first-time colonoscopy cohort, and improve the LBRD.
METHODS: The first-time colonoscopy with complete pathologic information were enrolled. The accuracy of LBRD strategy applied in diminutive polyps in different colonic segments was used as indicator to develop modified LBRD (mLBRD) strategy. Surveillance interval agreement with pathology-based reference was compared between LBRD and mLBRD. The ≥ 90% agreement with pathology was used as benchmark.
RESULTS: The polyps in sigmoid colon were significantly associated with higher proportion of neoplastic compared with polyps in rectum. The accuracy of LBRD applied in polyps in sigmoid colon were only 53.5%, which was significantly lower than that applied in polyps in other colonic segments. Thus, we hypothesized that mLBRD requiring pathology examination of diminutive polyps in sigmoid colon was more efficient in clinical use. The mLBRD significantly outperformed LBRD in surveillance interval agreement with pathology-based reference (90.2% vs. 83.4%, P <0.001), had lower proportion of patients assigned a longer surveillance interval (3.6% vs. 10.5%, P <0.001) and reached the benchmark, although the proportion of patients with an immediate surveillance interval recommendations and pathology examination avoided decreased.
CONCLUSIONS: The mLBRD, but not LBRD, achieved sufficient surveillance interval agreement with pathology-based surveillance interval assignment and reduced over 30% of pathology examinations.
A method of reducing or inhibiting the contraction or communication of viral illnesses is proposed. Application of a virucidal preparation containing one or more organic acids (e.g. malic acid) with or without a surfactant (e.g. sodium C 14 -C 16  olefin sulfonate) in a carrier agent (e.g. petrolatum) to the face of well individuals will reduce the chance that they contract illness with viral illnesses such as viral upper respiratory illnesses, influenza, viral gastroenteritis, viral rhinosinusitis, viral cold sores, and viral conjunctivitis. Application of said ointment to the nares of individuals with a VURI will reduce the chance they transmit the illness by reducing self-contamination of their hands when touching their nose. In addition, individuals suffering from a cold or influenza may reduce the duration or severity of illness by application of the nasal antiviral ointment. The ointment is most effective when applied with a clean applicator two or three times daily.
Morphine Sulfate Oral Solution is available in three concentrations: 10 mg per 5 mL, 20 mg per 5 mL and 100 mg per 5 mL (20 mg/mL).

Take care when prescribing and administering Morphine Sulfate Oral Solution to avoid dosing errors due to confusion between different concentrations and between mg and mL, which could result in accidental overdose and death. Take care to ensure the proper dose is communicated and dispensed. When writing prescriptions, include both the total dose in mg and the total dose in volume. Always use the enclosed calibrated oral syringe when administering Morphine Sulfate Oral Solution 100 mg per 5 mL (20 mg/mL) to ensure the dose is measured and administered accurately.

Selection of patients for treatment with morphine sulfate should be governed by the same principles that apply to the use of similar opioid analgesics. Individualize treatment in every case, using non-opioid analgesics, opioids on an as needed basis and/or combination products, and chronic opioid therapy in a progressive plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality, and the American Pain Society.
FIELD: medicine. SUBSTANCE: method involves applying psychometric control to patients having cardiovascular system function disorders at the fourteenth day of pharmacotherapy. No therapy effect being found, Niphedipin is administered as adjuvant remedy at a dose of 60 mg/day three times a day with 6 h long pauses. The dose is increased according to a scheme during the first 7 days. 15 mg dose is given in the first-second day, 30 mg during the third- fourth day, 45 mg during the fifth-sixth day, 60 mg at the seventh day. Depression intensity becoming less than 50% lower in terms of Hamilton scale at the fourteenth day after beginning Niphedipin consumption at a dose of 60 mg/day, Niphedipin dose is increased to 90 mg/day. EFFECT: enhanced effectiveness of treatment. 2 cl